|
Bahamondes L, Lavin P, Ojeda G, et al. Return of fertility
after discontinuation of the once-a-month injectable contraceptive
Cyclofem. Contraception 1997;55:307-10.
Bassol S, Garza-Flores J. Review of ovulation return upon discontinuation
of once-a-month injectable contraceptives. Contraception
1994;49:441-53.
Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns:
a review. Contraception 1988;38:129-56.
Benagiano G, Primiero FM, Bastianelli C, et al. Comparative
clinical evaluation of the effect on carbohydrate and lipid
metabolism of two norethisterone-containing hormonal contraceptives:
Mesigyna and TriNovum. Contraception
1997;55:295-300.
Bracken MB. Oral contraceptives and congenital malformations
in offspring. A review and meta-analysis of the prospective
studies. Obstet Gynecol 1990;76:552-57.
Coutinho EM, Spinola P, Barbosa I, et al. Multicenter, double-blind,
comparative clinical study on the efficacy and acceptability
of a monthly injectable contraceptive combination of 150 mg
dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate
compared to a monthly injectable contraceptive combination of
90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol
enanthate. Contraception 1997;55:175-81.
Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison
of bone density in adolescent girls receiving depot medroxyprogesterone
acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
J Pediatr 1996;129:671-76.
Cullins VE. Noncontraceptive benefits and therapeutic uses
of depot medroxyprogesterone acetate. J
Reprod Med 1996;41(Suppl 5):428-34.
Cundy T, Cornish J, Evans MC, et al. Recovery of bone density
in women who stop using medroxyprogesterone acetate. Br
Med J 1994;308:247-48.
Cundy T, Evans M, Roberts H, et al. Bone density in women receiving
depot-medroxyprogesterone acetate for contraception. Br
Med J 1991;303:13-16.
Cuong DT, My Hyong NT. Comparative phase III clinical trial
of two injectable contraceptive preparations, depot-medroxyprogesterone
acetate and Cyclofem, in Vietnamese women. Contraception
1996;54:169-79.
de Abood M, de Castillo Z, Guerrero F, et al. Effect of Depo-Provera
or Microgynon on the painful crises of sickle cell anemia patients.
Contraception 1997;56:313-16.
De Ceulaer K, Hayes R, Gruber C, et al. Medroxyprogesterone
acetate and homozygous sickle-cell disease. Lancet
1982;2:229-31.
Dennerstein GJ. Depo-Provera in the treatment of recurrent
vulvovaginal candidiasis. J Reprod
Med 1986;31:801-803.
Dorflinger LJ. Medical contraindications and issues for consideration
in the use of once-a-month injectable contraceptives. Contraception
1994;49:455-68.
Fraser IS. Vaginal bleeding patterns in women using once-a-month
injectable contraceptives. Contraception
1994;49:399-419.
Fraser IS, Weisberg E. A comprehensive review of injectable
contraception with special emphasis on depot-medroxyprogesterone
acetate. Med J Austral 1981;1(Spec
Suppl):3-20.
Garza-Flores J. Cyclofem/Cyclo-Provera: emerging countries’
perspective. Int J Gynecol Obstet
1998;62(Suppl 1):S31-S36.
Gray RH. Reduced risk of pelvic inflammatory disease with injectable
contraceptives (letter) Lancet 1985;1:1046.
Gray RH, Pardthaisong T. In utero exposure to steroid contraceptives
and survival during infancy. Am J Epidemiol
1991;134:804-11.
Gunning JE, Moyer D. The effect of medroxyprogesterone acetate
on endometriosis in the human female. Fertil
Steril 1967;18:759-74.
Hall PE, Bahamondes L, Diaz J, et al. Introductory study of
the once-a-month, injectable contraceptive Cyclofem in Brazil,
Chile, Colombia and Peru. Contraception
1997;56:353-59.
Hall PE, WHO Task Force on Research on Introduction and Transfer
of Technologies for Fertility Regulation. The introduction of
Cyclofem into national family planning programmes: experience
from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia.
Contraception 1994;49:489-507.
Hatcher RA, Trussell J, Stewart F, et al.Contraceptive
Technology. New York: Ardent Media, Inc., 1998.
IMAP statement on injectable contraception.
IPPF Med Bull, 1999;33(2).
Kaunitz AM. Depot medroxyprogesterone acetate contraception
and the risk of breast and gynecologic cancer. J
Reprod Med 1996;41(Suppl 5):419-27.
Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception:
an update for U.S. clinicians. Int J
Fertil Womens Med 1998;43:73-83.
Kesserü EV, Aydinlik S, Etchepareborda JJ. Multicentred,
phase III clinical trial of norethisterone enanthate 50 mg plus
estradiol valerate 5 mg as a monthly injectable contraceptive;
final three-year report. Contraception
1994;50:329-37.
Kistner RW. The treatment of endometriosis by inducting pseudopregnancy
with ovarian hormones: a report of fifty-eight cases. Fertil
Steril 1959;10:539-56.
Koetsawang S. Once-a-month injectable contraceptives: efficacy
and reasons for discontinuation. Contraception
1994;49:387-98.
Koetsawang, S. The effects of contraceptive methods on quality
and quantity of breastmilk. Int J Gynecol
Obstet 1987;25(Suppl):115-27.
Jimenez J, Ochoa M, Soler MP, et al. Long-term follow-up of
children breastfed by mothers receiving depo-medroxyprogesterone
acetate. Contraception 1984;30:523-33.
Lande RE. New era for injectables. Population
Reports 1995;Series K(5).
Lei Z-W, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling
on discontinuation rates in Chinese women given depot-medroxyprogesterone
acetate for contraception. Contraception
1996;53:357-61.
Lumbiganon P. Depo-medroxyprogesterone acetate (DMPA) and cancer
of the endometrium and ovary. Contraception
1994;49:203-12.
Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter,
bleeding, and weight changes in U.S. women using progestin-only
contraceptives. Contraception
1995;51:149-53.
Mattson RH, Cramer JA, Caldwell BV, et al. Treatment of seizures
with medroxyprogesterone acetate: preliminary report. Neurology
1984;34:1255-58.
Naessen T, Olsson S-E, Gudmundson J. Differential effects on
bone density of progestogen-only methods for contraception in
pre-menopausal women. Contraception
1995;52:35-39.
Pardthaisong T. Return of fertility after use of the injectable
contraceptive Depo-Provera: updated data analysis. J
Biosocial Sci 1984;16:23-24.
Pardthaisong T, Gray R. In utero exposure to steroid contraceptives
and outcome of pregnancy. Am J Epidemiol
1991;134:795-803.
Pardthaisong T, Yenchit C, Gray R. The long-term growth and
development of children exposed to Depo-Provera during pregnancy
or lactation. Contraception
1992;45:313-24.
Paul C, Skegg DCG, Spears GFS. Depot-medroxyprogesterone (Depo-Provera)
and risk of breast cancer. Br Med J
1989;299:759-62.
Population Council. Focus on the Philippine DMPA reintroduction
program: continuing users vs. drop-outs. Population
Council Research News: Asia and Near East Operations Research
and Technical Assistance Project 1996;Apr(7):1-2.
Rosenblatt KA, Thomas DB. Depot-medroxyprogesterone acetate
(DMPA) and risk of liver cancer. Int
J Cancer 1991;49:182-85.
Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative
clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given
monthly by intramuscular injection to Chinese women. I. Contraceptive
efficacy and side effects. Contraception
1995;51:167-83.
Sang GW, Shao QX, Ge RS, et al. A multicentred phase III comparative
clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given
monthly by intramuscular injection to Chinese women. II. The
comparison of bleeding patterns. Contraception
1995;51:185-92.
Scholes D, LaCroix AZ, Ott SM, et al. Bone mineral density
in women using depot-medroxyprogesterone acetate for contraception.
Obstet Gynecol 1999;93:233-38.
Schwallie PC, Assenzo JR. The effect of depot-medroxyprogesterone
acetate on pituitary and ovarian function, and the return of
fertility following its discontinuation: a review. Contraception
1974;10:181-202.
Skegg DCG, Noonan EA, Paul C, et al. Depot-medroxyprogesterone
acetate and breast cancer: a pooled analysis of the World Health
Organization and New Zealand studies. J
Am Med Assoc 1995;273:799-804.
Simpson JL, Phillips OP. Spermicides, hormonal contraception
and congenital malformations. Adv Contracept
1990;6:141-67.
Stanford JL, Thomas DB. Depot-medroxyprogesterone acetate and
risk of epithelial ovarian cancer. Int
J Cancer 1991;49:191-95.
Technical Guidance Working Group. Recommendations
for Updating Selected Practices in Contraceptive Use: Results
of a Technical Meeting, Volume I. Washington: US Agency
for International Development, 1994.
Technical Guidance/Competence Working Group. Recommendations
for Updating Selected Practices in Contraceptive Use: Results
of a Technical Meeting, Volume II. Washington: US Agency
for International Development, 1997.
Technical Guidance/Competence Working Group, World Health Organization,
Division of Family Health. Family planning methods: new guidance.
Population Reports 1996;44:1-48.
Thomas DB, Noonan EA. Breast cancer and depot-medroxyprogesterone
acetate: a multinational study. Lancet
1991;338:833-38.
Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA)
and risk of endometrial cancer. Int
J Cancer 1991;49:186-90.
Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA)
and risk of invasive squamous cell cervical cancer. Contraception
1992;45:299-312.
Thomas DB, Ye Z, Ray RM, et al. Cervical carcinoma in situ
and use of depot-medroxyprogesterone acetate (DMPA). Contraception
1995;51:25-31.
Tieng P. Return to fertility after use of the injectable contraceptive
Depo-Provera: updated analysis. Oklahoma
City: Second Asian Regional Workshop on Injectable Contraceptives.
1992:30-38.
Toppozada MK. Existing once-a-month combined injectable contraceptives.
Contraception 1994;49:293-301.
Toppozada M, Onsy FA, Fares E, et al. The protective influence
of progesterone-only contraception against vaginal moniliasis.
Contraception 1979;20:99-103.
United Nations, Department for Economic and Social Information
and Policy Analysis. Levels and Trends
of Contraceptive Use as Assessed in 1994. New York: United
Nations, 1996.
Westhoff C. Depot medroxyprogesterone acetate contraception:
metabolic parameters and mood changes. J
Reprod Med 1996;41(5 Suppl):401-06.
WHO. Facts about once-a-month injectable contraceptives: memorandum
from a WHO meeting. Bull WHO
1993;70:677-89.
WHO. Improving Access to Quality
Care in Family Planning: Medical Eligibility Criteria for Initiating
and Continuing Use of Contraceptive Methods. Geneva:
WHO, 1996.
WHO Collaborative Study of Cardiovascular Disease and Steroid
Hormone Contraception. Cardiovascular disease and use of oral
and injectable progestogen-only contraceptives and combined
injectable contraceptives. Results of an international, multicenter,
case-control study. Contraception
1998;57:315-24.
WHO Task Force for Epidemiological Research on Reproductive
Health. Progestogen-only contraceptives during lactation: I.
Infant growth. Contraception
1994;50:35-53.
WHO Task Force for Epidemiological Research on Reproductive
Health. Progestogen-only contraceptives during lactation: II.
Infant development. Contraception
1994;50:55-68.
WHO Task Force on Intrauterine Devices. PID associated with
fertility-regulating agents. Contraception
1984;30:1-21.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. A multicentred phase III comparative clinical trial
of depot-medroxyprogesterone acetate given three-monthly at
doses of 100 mg or 150 mg: I. Contraceptive efficacy and side
effects. Contraception 1986;34:223-35.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. A multicentred phase III comparative clinical trial
of depot-medroxyprogesterone acetate given three-monthly at
doses of 100 mg or 150 mg: II. The comparison of bleeding patterns.
Contraception 1987;35:591-610.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. A multicentred phase III comparative study of two
hormonal contraceptive preparations given one-a-month by intramuscular
injection: I. Contraceptive efficacy and side effects. Contraception
1988;37:1-20.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. A multicentred phase III comparative study of two
hormonal contraceptive preparations given one-a-month by intramuscular
injection: II. Comparison of bleeding patterns. Contraception
1989;40:531-51.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. Comparative study of the effects of two once-a-month
injectable steroidal contraceptives (Mesigyna and Cyclofem)
on glucose metabolism and liver function. Contraception
1998;57:71-81.
WHO Task Force on Long-acting Systemic Agents for Fertility
Regulation. Multinational comparative clinical trial of long-acting
injectable contraceptives: norethisterone enanthate given in
two dosage regimens and depot-medroxyprogesterone acetate; final
report. Contraception 1983;28:1-20.
|
